New targeted drug with chemo for rare EGFR lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted pill (andamertinib) with or without standard chemotherapy, compared to chemotherapy alone, for people with a rare type of EGFR-mutated lung cancer that has not been treated before. It aims to find which approach works better against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of non-small cell lung cancer (NSCLC) called non-squamous that is stage IIIB, IIIC, or IV (advanced and cannot be removed by surgery).
- Your cancer has a rare (atypical) EGFR gene change, and you have not had any previous treatment for advanced disease.
- You are at least 18 years old, able to care for yourself (ECOG 0 or 1), and expected to live at least 12 weeks.
- You have at least one tumor that can be measured on scans (like a CT or MRI).
- You do not have serious heart, lung, or other health conditions that would make the study unsafe, and you are willing to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
This trial tests PLB1004, an oral medication that targets a specific gene mutation (EGFR) in non-small cell lung cancer. It may be an option if you have this mutation and are looking for a new treatment.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
This trial tests a new drug (ANS014004) combined with an EGFR-targeted therapy for people with advanced non-small cell lung cancer that has an EGFR mutation. It is for those whose cancer has gotten worse after standard treatments or who cannot take them.
This study tests three different targeted pills (osimertinib, afatinib, dacomitinib) in people with advanced EGFR-mutated lung cancer who haven't had targeted therapy before. The goal is to find which pill works best and has the fewest side effects.
This trial tests a combination of two experimental drugs (vebreltinib plus PLB1004) against standard chemotherapy for people with a specific type of advanced lung cancer (EGFR mutation positive, MET positive) that has gotten worse after prior EGFR-targeted therapy.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.